<DOC>
	<DOCNO>NCT01258088</DOCNO>
	<brief_summary>The purpose study determine much drug absorb throughout body applied skin .</brief_summary>
	<brief_title>Safety Study Ointment Treatment Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>White male , 18 55 year ( inclusive ) age time randomization . Body weight 6090 kg ( Body Mass Index [ BMI ] 19 30 kg/m2 [ inclusive ] ) . Willing able comply study instruction commit followup visit . Have adequate venous access permit repeat PK sample . Ability understand , agree sign study Informed Consent Form ( ICF ) prior initiation protocolrelated procedure . Nonsmokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior administration study medication ) . For psoriasis patient ( addition criterion ) : Clinical diagnosis stable plaquetype psoriasis active plaque involve 5 % 20 % total BSA exclude face , scalp groin . History serious adverse reaction hypersensitivity drug ; know allergy test product ( ) components test product ( ) history hypersensitivity ; allergic reaction study preparation describe Investigator 's Brochure . Any clinically significant central nervous system ( e.g. , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic gastrointestinal condition history condition , opinion Investigator may place subject unacceptable risk participant trial may interfere distribution , metabolism excretion drug . Abnormal physical finding clinical significance Screening examination Baseline would interfere objective study . History orthostatic hypotension ( increase HR ≥20 bpm accompany ≥20 mm Hg drop SBP and/or ≥10 mm Hg drop DBP ) present Screening . Clinically significant abnormal laboratory value ( determine Investigator ) Screening evaluation . Presence history allergy require acute chronic treatment ( except seasonal allergic rhinitis ) . 12lead ECG obtain Screening : PR &gt; 240 msec , QRS &gt; 110 msec QTc &gt; 450 msec , bradycardia ( &lt; 50 bpm ) clinically significant minor ST wave change Screening ECG , change Screening ECG would interfere measurement QT interval . Major surgical intervention within 6 month study . Has positive prestudy Hepatitis B surface antigen ; positive Hepatitis C ( HCV ) antibody detectable HCV ribonucleic acid ( RNA ) ; positive HIV antibody result . Use prescription nonprescription drug , include vitamin supplement , herbal dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication , use St. John 's Wort within 28 day prior first dose study medication . However , Investigator study team review medication use case case basis determine use would compromise subject safety interfere study procedure data interpretation . By exception , subject may take paracetamol acetaminophen ( ≤2 g/day ) ibuprofen ( ≤1600 mg/day ) 48 h prior first dose study medication . Has history regular alcohol consumption average &gt; 14 drinks/week ( 1 drink [ 100 mL wine 280 mL standard strength beer 30 mL 80 proof distil spirit ] ) within 6 month Screening visit . Loss 500 mL blood 3 month period study , e.g. , blood donor . People follow vegetarian vegan diet . Symptoms significant somatic mental illness four week period precede drug administration . History drug abuse dependence within 12 month study . Positive prestudy urine drug alcohol screen . A minimum list drug screen include benzodiazepine , opiate , methadone metabolite ( EDDP ) , sympathomimetic amine , cannabinoids , barbiturate , cocaine , ethanol . ( Suspected false positive result may repeat discretion Investigator . ) Concurrent recent ( within 60 day ) participation another drug device research study . Considered Investigator unsuitable candidate study . Use AN2728 previous clinical trial . For psoriasis patient ( addition exclusion criterion ) : Spontaneously improve rapidly deteriorate psoriatic plaque pustular/exfoliative , guttate , erythrodermic nonplaque form psoriasis . Currently druginduced psoriasis ( new onset exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) . Other serious skin disorder ( ) . Use nonbiologic systemic antipsoriatic therapy ( e.g. , corticosteroid , PUVA , UVB , retinoids , methotrexate , cyclosporine , immunosuppressive agent ) biologic therapy ( e.g. , alefacept , etanercept , adalimumab , ustekinumab ) within four week prior enrollment concurrently study . Use topical treatment know beneficial effect psoriasis , include limited corticosteroid , retinoids , vitamin D derivative , tar anthralin , within past two week prior enrollment concurrently study . Systemic medication medical condition know affect psoriasis ( e.g. , lithium , beta adrenergic blocker ) within past four week prior enrollment concurrently study . Use emollients/moisturizers area ( ) treat within two day prior enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>psoriasis</keyword>
</DOC>